Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V116 pneumococcal vaccine with influenza vaccine in adults ≥50 years
NCT05526716Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pneumococcal 21-valent conjugate vaccine in Pneumococcal pneumonia (PP), sponsored by Merck & Co.. Started Sep 2022; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT05526716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526716.